Pharmaceutical

Zevra sells priority review voucher for $150m to support drug launches

Zevra will use the $150m to support the commercial launches of rare disease drugs Miplyffa and Olpruva.

Mar 1, 2025 - 06:00
Zevra sells priority review voucher for $150m to support drug launches
Zevra will use the $150m to support the commercial launches of rare disease drugs Miplyffa and Olpruva.
Read the original article

Tags:

Previous Article

Alltrna plans to tackle rare diseases using tRNA-based therapies

Next Article

New EU trial regulations could expedite approvals and address shortages

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GSK signs licence deal with Scynexis for fungal infection treatment

GSK signs licence deal with Scynexis for fungal infecti...

Mar 31, 2023

STAT+: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result

STAT+: Consumer health advocate Sid Wolfe was a thorn i...

Jan 2, 2024

RedHill and Hyloris sign agreement for Bekinda’s development

RedHill and Hyloris sign agreement for Bekinda’s develo...

Feb 27, 2025